shutterstock_1696929460_m_foto

M-Foto / Shutterstock.com

12 August 2021AmericasAlex Baldwin

Brazil passes compulsory licence bill for COVID-19 vaccines

The Brazilian Senate Plenary has approved a bill that will allow President Bolsonaro to waive patent protections for COVID-19 vaccines.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Brazil Supreme Court suspends drug patent extensions

8 April 2021 Brazil’s highest court has suspended extensions of drug patents due to the public health emergency caused by COVID-19.

Australia backs COVID-19 vaccine waiver

9 September 2021 Australia will waive IP protections for COVID-19 vaccines to enable more cost-effective copycat versions to be manufactured in developing countries, in the wake of mounting pressure from human rights groups and governments worldwide.

More on this story

Australia backs COVID-19 vaccine waiver

9 September 2021 Australia will waive IP protections for COVID-19 vaccines to enable more cost-effective copycat versions to be manufactured in developing countries, in the wake of mounting pressure from human rights groups and governments worldwide.

Brazil Supreme Court suspends drug patent extensions

8 April 2021 Brazil’s highest court has suspended extensions of drug patents due to the public health emergency caused by COVID-19.

More on this story

Australia backs COVID-19 vaccine waiver

9 September 2021 Australia will waive IP protections for COVID-19 vaccines to enable more cost-effective copycat versions to be manufactured in developing countries, in the wake of mounting pressure from human rights groups and governments worldwide.

Brazil Supreme Court suspends drug patent extensions

8 April 2021 Brazil’s highest court has suspended extensions of drug patents due to the public health emergency caused by COVID-19.

More features

Novartis shields eye-drop patent at European Patent Office

CREATES Act unfairly tips the scales to generics

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York

UPC deals further blow to Dexcom in glucose monitor dispute with Abbott

‘A marathon and a sprint at the same time’: How we won $452m damages